Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Common Equity (2017 - 2021)

Cogent Biosciences (COGT) has 4 years of Common Equity data on record, last reported at $197.2 million in Q3 2021.

  • For Q3 2021, Common Equity rose 989.5% year-over-year to $197.2 million; the TTM value through Sep 2021 reached $197.2 million, up 989.5%, while the annual FY2020 figure was $234.7 million, 638.83% up from the prior year.
  • Common Equity reached $197.2 million in Q3 2021 per COGT's latest filing, down from $212.8 million in the prior quarter.
  • Across five years, Common Equity topped out at $234.7 million in Q4 2020 and bottomed at -$61.3 million in Q1 2018.
  • Average Common Equity over 4 years is $79.1 million, with a median of $49.3 million recorded in 2019.
  • Peak YoY movement for Common Equity: plummeted 177.47% in 2020, then surged 1005.99% in 2021.
  • A 4-year view of Common Equity shows it stood at $60.2 million in 2018, then tumbled by 47.27% to $31.8 million in 2019, then skyrocketed by 638.83% to $234.7 million in 2020, then dropped by 15.95% to $197.2 million in 2021.
  • Per Business Quant database, its latest 3 readings for Common Equity were $197.2 million in Q3 2021, $212.8 million in Q2 2021, and $226.8 million in Q1 2021.